Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

Predictors of Discontinuation of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

SANDEEP K. AGARWAL, ROBERTA J. GLASS, NANCY A. SHADICK, JONATHAN S. COBLYN, RONALD J. ANDERSON, NANCY E. MAHER, MICHAEL E. WEINBLATT and DANIEL H. SOLOMON
The Journal of Rheumatology September 2008, 35 (9) 1737-1744;
SANDEEP K. AGARWAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Sandeep.K.Agarwal@uth.tmc.edu
ROBERTA J. GLASS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NANCY A. SHADICK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JONATHAN S. COBLYN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RONALD J. ANDERSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NANCY E. MAHER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL E. WEINBLATT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL H. SOLOMON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective

Tumor necrosis factor-α (TNF) inhibitors have transformed management of rheumatoid arthritis (RA); however, many patients discontinue TNF inhibitors. Our goal was to determine the discontinuation rate of TNF inhibitors and identify predictors associated with discontinuation.

Methods

Enrollees in the Brigham RA Sequential Study (BRASS) formed the eligible cohort. Patients reporting use of a TNF inhibitor with at least 6 months of followup were followed until reporting TNF inhibitor discontinuation or their last study visit if they continued therapy. Potential predictor variables, including demographic and clinical data assessed at baseline and 6 months prior to study endpoint, were identified using a Cox proportional regression.

Results

Among 961 patients in BRASS, 503 were using a TNF inhibitor with at least 6 months of followup in BRASS (mean length of followup 39 mo, SD 13). Two hundred ten patients (42%) reported discontinuation of TNF inhibitor. Higher physician global scores (hazard ratio 1.27, 95% CI 1.18–1.38) and RA Disease Activity Index scores (HR 1.13, 95% CI 1.05–1.22) 6 months prior to stopping the TNF inhibitor and higher number of TNF inhibitors used previously (HR 1.30, 95% CI 1.03–1.66) were associated with discontinuation of TNF inhibitor. Prior use of synthetic disease modifying antirheumatic drugs (HR 0.50, 95% CI 0.34–0.72) and more years of cumulative methotrexate use (HR 0.24, 95% CI 0.12–0.47) were inversely associated with discontinuation of TNF inhibitor.

Conclusion

These data demonstrate that a significant number of patients with RA discontinue TNF inhibitors. Several easily characterized clinical variables have a modest predictive association with reduced probability of TNF inhibitor discontinuation.

Key Indexing Terms:
  • RHEUMATOID ARTHRITIS
  • TUMOR NECROSIS FACTOR INHIBITOR
  • PREDICTOR
  • DISCONTINUATION

Footnotes

  • S.K. Agarwal, MD, PhD, Division of Rheumatology, Immunology, Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, and Division of Rheumatology, Department of Internal Medicine, The University of Texas Health Science Center at Houston; R.J. Glass, MS; N.A. Shadick, MD; J.S. Coblyn, MD; R.J. Anderson, MD; N.E. Maher, MS; M.E. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology, Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School.

  • Establishment of the Brigham RA Sequential Study cohort was supported by Millennium Inc. Dr. Agarwal is a past recipient of the Abbott Scholar Award in Rheumatology Research. Dr. Shadick is supported by grants from Millennium Inc., National Institutes of Health/NIAMS R01 AR49880, Centers for Disease Control, and the Bristol Myers Squibb Foundation [Patient Centered Outcomes (PACO) Initiative]. Dr. Weinblatt is supported by a grant from the Arthritis Foundation and its Engalitcheff Arthritis Outcomes Initiative, and the Bristol Myers Squibb Foundation (PACO Initiative). Dr. Solomon is supported by grants from the NIH (AR48616, AG027066), the Arthritis Foundation, and the Engalitcheff Arthritis Outcomes Initiative.

    • Accepted for publication April 15, 2008.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 35, Issue 9
1 Sep 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of Discontinuation of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Predictors of Discontinuation of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
SANDEEP K. AGARWAL, ROBERTA J. GLASS, NANCY A. SHADICK, JONATHAN S. COBLYN, RONALD J. ANDERSON, NANCY E. MAHER, MICHAEL E. WEINBLATT, DANIEL H. SOLOMON
The Journal of Rheumatology Sep 2008, 35 (9) 1737-1744;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Predictors of Discontinuation of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
SANDEEP K. AGARWAL, ROBERTA J. GLASS, NANCY A. SHADICK, JONATHAN S. COBLYN, RONALD J. ANDERSON, NANCY E. MAHER, MICHAEL E. WEINBLATT, DANIEL H. SOLOMON
The Journal of Rheumatology Sep 2008, 35 (9) 1737-1744;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Salivary Gland Focus Score Is Associated With Myocardial Fibrosis in Primary Sjögren Syndrome Assessed by a Cardiac Magnetic Resonance Approach
  • Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting
  • Effect of Stem Cell Injections on Osteoarthritis-related Structural Outcomes: A Systematic Review
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire